Osteoporosis is a progressive, systemic, skeletal disease characterized
by decreased bone mass and microarchitectural deterioration of bone
tissue leading to increased bone fragility and susceptibility to
The more risk factors (eg history of fracture, advanced age,
comorbidities, etc) that are present, the greater the risk
Abaloparatide increases bone mineral density (BMD) at the ultradistal radius along with lower risk of wrist fracture compared with placebo and teriparatide in postmenopausal women with osteoporosis, according to a study presented at The Endocrine Society Annual Meeting (ENDO 2017) in Orlando, Florida, US.
The combination of age, weight, menopausal status, chronic joint pain, and right handgrip strength is a good tool to predict spinal osteoporosis in midlife Asian women, and may be an improvement over the Osteoporosis Self-assessment Tool for Asians (OSTA), according to a study presented at the 6th Asia-Pacific Osteoporosis Meeting (IOF Regionals 2016) held recently in Singapore.
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.